11 Results

People

  1. Palomba
    Palomba
  2. Gerecitano
    Gerecitano
  3. Hamilton
    Hamilton
  4. Hamlin
    Hamlin
  5. Kumar
    Kumar
  6. Matasar
    Matasar
  7. Moskowitz
    Moskowitz
  8. Noy
    Noy
  9. Portlock
    Portlock
  10. Younes
    Younes

Groups

  1. Center for Hematologic Malignancies (11)
  2. Department of Medicine (11)
  3. Hematologic Malignancies, Division of (11)
  4. Lymphoma (11)
  5. Adult Leukemia (3)
  6. Executive Committee, Center for Hematologic Malignancies (2)
  7. Sloan Kettering Institute Postdocs (2)
  8. Survivorship Research (2)
  9. Advanced Practice Providers (1)
  10. Biostatistics Service (1)
  1. "Clinical Lymphoma, Myeloma and Leukemia"
  2. "Maria Palomba"
Formats
  1. Meeting Abstract (7)
  2. Journal Article (3)
  3. Editorial (1)
Groups
  1. Center for Hematologic Malignancies (11)
  2. Department of Medicine (11)
  3. Hematologic Malignancies, Division of (11)
  4. Lymphoma (11)
  5. Adult Leukemia (3)
  6. Executive Committee, Center for Hematologic Malignancies (2)

More Groups

People
  1. Maria Palomba (11)
  2. Anas Younes (2)
  3. Andrew Zelenetz (2)
  4. Anita Kumar (2)
  5. Anthony Mato (2)
  6. Ariela Noy (2)

More People

Years
  1. 2024 (1)
  2. 2023 (2)
  3. 2022 (4)
  4. 2021 (2)
  5. 2018 (1)
  6. 2017 (1)
Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (11)
Publishers
  1. Elsevier Inc. (11)

Results (11)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A comparison of 3-year follow-up of ZUMA-5 (axicabtagene ciloleucel) with SCHOLAR-5 in relapsed/refractory follicular lymphoma
    Editorial

    Ghione, P.; Palomba, M. L.; Ray, M. D.; Limbrick-Oldfield, E. H.; Owen, J.; Kanters, S.; Bobillo, S.; Ribiero, M. T.; Jacobson, C. A.; Neelapu, S. S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Lisocabtagene maraleucel (liso-cel) in R/R MCL: Primary analysis results from the mcl cohort of the single-arm, multicenter, phase I seamless design TRANSCEND NHL 001 study
    Meeting Abstract

    Palomba, M. L.; Siddiqi, T.; Gordon, L. I.; Kamdar, M.; Lunning, M.; Hirayama, A. V.; Abramson, J. S.; Arnason, J.; Ghosh, N.; Mehta, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • TRANSCEND FL: Phase II study results of lisocabtagene maraleucel (liso-cel) in patients with R/R follicular lymphoma (FL)
    Meeting Abstract

    Nastoupil, L. J.; Dahiya, S.; Palomba, M. L.; Garcia-Sancho, A. M.; Ortega, J. L. R.; Kuruvilla, J.; Jager, U.; Cartron, G.; Izutsu, K. I.; Dreyling, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: Initial experience in two clinical trials
    Meeting Abstract

    Qualls, D.; Monette, S.; Sethi, S.; Dogan, A.; Roshal, M.; Senechal, B.; Wang, X.; Riviere, I.; Sadelain, M.; Brentjens, R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study
    Meeting Abstract

    Cohen, J. B.; Shah, N. N.; Alencar, A. J.; Gerson, J. N.; Patel, M. R.; Fakhri, B.; Jurczak, W.; Tan, X. N.; Lewis, K. L.; Fenske, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Combination of atezolizumab and tazemetostat in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from a phase Ib study
    Journal Article

    Palomba, M. L.; Cartron, G.; Popplewell, L.; Ribrag, V.; Westin, J.; Huw, L. Y.; Agarwal, S.; Shivhare, M.; Hong, W. J.; Raval, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Combination of atezolizumab and obinutuzumab in patients with relapsed/refractory follicular lymphoma and diffuse large B‐cell lymphoma: Results from a phase 1b study
    Journal Article

    Palomba, M. L.; Till, B. G.; Park, S. I.; Morschhauser, F.; Cartron, G.; Marks, R.; Shivhare, M.; Hong, W. J.; Raval, A.; Chang, A. C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Pirtobrutinib (LOXO-305), a next-generation, highly selective, non-covalent Bruton's tyrosine kinase inhibitor in previously treated mantle cell lymphoma and other non-Hodgkin lymphomas: Phase 1/2 BRUIN study results
    Meeting Abstract

    Cohen, J. B.; Shah, N. N.; Alencar, A. J.; Gerson, J. N.; Patel, M. R.; Fahkri, B.; Jurczak, W.; Tan, X. N.; Lewis, K. L.; Fenske, T. S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Noninvasive monitoring of mantle cell lymphoma by immunoglobulin gene next-generation sequencing in a phase 2 study of sequential chemoradioimmunotherapy followed by autologous stem-cell rescue
    Journal Article

    Kumar, A.; Bantilan, K. S.; Jacob, A. P.; Park, A.; Schoninger, S. F.; Sauter, C.; Ulaner, G. A.; Casulo, C.; Faham, M.; Kong, K. A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Ibrutinib/rituximab versus placebo/rituximab: A randomized, phase 3 trial in Waldenström's macroglobulinemia (iNNOVATE)
    Meeting Abstract

    Palomba, M. L.; Dimopoulos, M. A.; Tedeschi, A.; Trotman, J.; García-Sanz, R.; MacDonald, D.; Leblond, V.; Mahe, B.; Herbaux, C.; Tam, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2018)

    Fulltext@MSK | Save